Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment
US biopharma company Catabasis Pharmaceuticals has wrapped up enrollment for the phase 3 PolarisDMD clinical trial designed to evaluate edasalonexent, an NF-kB inhibitor, in Duchenne muscular dystrophy (DMD). The biopharma company said that the target enrollment of 125 boys was surpassed owing to strong interest from its 40 clinical sites across eight countries along with […]
The post Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment appeared first on PharmaNewsDaily.com.
Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal
Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US. Shareholders of Dova Pharmaceuticals will be […]
The post Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal appeared first on PharmaNewsDaily.com.
Currax Pharmaceuticals acquires Nalpropion Pharmaceuticals
Currax Pharmaceuticals, a specialty biopharma company having branded and generic drug businesses, has acquired Nalpropion Pharmaceuticals for an undisclosed price, as per the latest pharma acquisition news. Through the acquisition, Currax gains the global rights to CONTRAVE (naltrexone HCl and bupropion HCl extended release), a prescribed weight-loss drug in the US, which has patent protection till […]
The post Currax Pharmaceuticals acquires Nalpropion Pharmaceuticals appeared first on PharmaNewsDaily.com.
Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials
Meissa Vaccines, a US biotech company focused on developing vaccines for the prevention of viral respiratory infections, has raised $30 million in a Series A financing with Morningside Ventures. The US biotech company plans to use the new capital for the expansion of its team, for undertaking phase 1 and 2 clinical trials for its […]
The post Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials appeared first on PharmaNewsDaily.com.
Progenity buys assets of ingestible device company Medimetrics
US biotech company Progenity has acquired patented assets of Medimetrics, a Dutch ingestible device company, for an undisclosed price. The acquired portfolio for ingestible device technologies includes 137 granted patents to go along with 15 pending applications in the US, Europe, Japan, and China. The Medimetrics assets will further consolidate Progenity’s intellectual property portfolio. Furthermore, […]
The post Progenity buys assets of ingestible device company Medimetrics appeared first on PharmaNewsDaily.com.
Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors
Amphivena Therapeutics funding round : Amphivena Therapeutics has raised $62 million in a Series C financing round to expand the clinical development of its lead candidate AMV564 into solid tumors and also to develop its T cell engagement portfolio. Based in California, Amphivena Therapeutics is a clinical-stage immuno-oncology company focused on developing T cell engager […]
The post Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors appeared first on PharmaNewsDaily.com.
Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome
Annexon Biosciences has bagged the fast track designation for its C1q inhibitor ANX005 from the US Food and Drug Administration (FDA) for the treatment of Guillain-Barré Syndrome (GBS). Considered to be a rare, acute, antibody-mediated autoimmune disease, Guillain-Barré Syndrome affects the peripheral nervous system for which there are no approved therapies in the US till […]
The post Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome appeared first on PharmaNewsDaily.com.
Novo Nordisk bags Rybelsus FDA approval for type 2 diabetes
Rybelsus FDA approval : Danish pharma company Novo Nordisk has bagged approval from the US Food and Drug Administration (FDA) for Rybelsus (semaglutide) oral tablets for its use in patients with type 2 diabetes. The FDA approval for Rybelsus is to improve control of blood sugar in addition to diet and exercise in adults having […]
The post Novo Nordisk bags Rybelsus FDA approval for type 2 diabetes appeared first on PharmaNewsDaily.com.
Opentrons launches fully automated thermocycler at $4,000
Biotech startup Opentrons has launched a fully automated thermocycler, priced at $4,000, which has been designed to help biologists with automated end-to-end PCR based workflow. According to Opentrons, there are several products that are currently available in the market which enable biologists to automate important segments of their workflows. However, human assistance is needed for […]
The post Opentrons launches fully automated thermocycler at $4,000 appeared first on PharmaNewsDaily.com.
Aptorum to develop drugs for treatment of obesity and neuroblastoma
Aptorum Group said that it will undertake the development of CLS-1 microbiome drug candidate and certain repurposed drug candidates for the treatment of obesity and neuroblastoma, respectively. Based in Hong Kong, Aptorum Group is a pharma company focused on the development of new drugs to treat unmet medical needs. The company said that its wholly-owned subsidiary […]
The post Aptorum to develop drugs for treatment of obesity and neuroblastoma appeared first on PharmaNewsDaily.com.